Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of SYNLOGIC INC. DL-,001
Analyst Grade Summary
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
0
10
3
1
0
No Price
28.04.2026 15:58
Current Prices from SYNLOGIC INC. DL-,001
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
NASDAQ
SYBX
USD
28.04.2026 15:58
0,64 USD
0,005 USD
+0,79 %
Share Float & Liquidity
Free Float60,65 %
Shares Float7,1 M
Shares Outstanding11,7 M
Company Profile for SYNLOGIC INC. DL-,001 Share
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
